Ironwood Pharmaceuticals Inc. (IRWD): 0 Analysts rated it as Sell IRWD


Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) changes shares on Wednesday trading session, with a change of -0.87% or -$0.09 shares. The trading starts at $9.82 and closed at $9.73 throughout the day. The trading session low price was $9.47 and day high was $9.82 on Wednesday, August 05. After the session, the Healthcare sector daily volume shifted to 2.15 million while its average volume is 2.24M. In other hand, the IRWD market cap reached to $1.58B. While, its current target price is $12.20.

On May 27, 2020, BRIEF-Ironwood, Abbvie Report MD-7246 Phase 2 Data In Patients With Abdominal Pain Associated With IBS-D. According to the news reported on Reuters, * IRONWOOD AND ABBVIE REPORT TOP-LINE PHASE II DATA FOR MD-7246 IN PATIENTS WITH ABDOMINAL PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D)

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 5.47% and down -5.16% for month. Its quarterly performance was -7.31% below, while its half year performance is down -22.45%. IRWD yearly performance stood at negative -6.13% and fall -27.57% for year-to-date. Current recommendation for Ironwood Pharmaceuticals Inc. is 2.70.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. IRWD EPS (TTM) for 12-month is 0.54. EPS for this year is 129.70%, while for the next year its value is 0.55. Its EPS Q/Q reached 114.80%. It has an EPS of 17.80% up for past five years.

Let’s take a look on the analyst recommendations on IRWD for the current month and previous month. For the current month, 2 of 6 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 4 as Hold. As compared with the previous month ratings, 7 analysts participate in stock recommendation. Out of 7, 0 rated it sell, 2 rated it as Buy and 5 as Hold Ratings. On the other hand, target price ranges from $10.00 – $14.00. Average target price for IRWD was reached at $12.17.

Wellington Management Company, LLP, Brown Capital Management, Inc. and Vanguard Group, Inc. (The) are the top three holders in Ironwood Pharmaceuticals Inc. (IRWD) stock. On Mar 30, 2020, Wellington Management Company, LLP has 22.06 million shares which valued 222.63 million. On Mar 30, 2020, Brown Capital Management, Inc. owned 17.96 million shares which valued at 181.22 million. On Mar 30, 2020, Vanguard Group, Inc. (The) has a total of 16.34 million shares which valued at 164.88 million. In the end, Vanguard Group, Inc. (The) have 10.25% shares outstanding of Ironwood Pharmaceuticals Inc. (IRWD) on Mar 30, 2020. The insider ownership moved to 2.00%.

The company posted an EPS (TTM) of 0.54. According to the most recent quarter report on (Jun 2020), 6 analysts estimated an average EPS of 0.09, while 0.1 EPS posted a year ago period. Analyst Estimated EPS for IRWD published in the report was $0.03 – $0.11 during the same period. Comparing with last year, the average estimated EPS was 0.1 which is higher than 0.04 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for IRWD fall -12.55% for period of 200 days. SMA for 50 days was -3.14% which is showing red signal, while SMA-20 was -2.08%. The moving average value for Ironwood Pharmaceuticals Inc. (IRWD) is 10.62 and 9.93 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in IRWD stock. On Jun 10, OLANOFF LAWRENCE S, Director, sold 11,350 trading shares at the cost of $10.06, which valued at 0.11 million. On May 11, Rickard Jason, SVP, Chief Operating Officer, sold 510 shares at the cost of $10.35, with total shares of 234,580. On May 11, MCCOURT Thomas A, President, sold 1,697 shares at the cost of 10.35. After this transaction, MCCOURT Thomas A total shares reached to 319,847 which valued at 17564.0.